NGNicolas Goossens

Nicolas Goossens

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nicolas Goossens has a total of 201 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Expanding hepatocellular carcinoma surveillance strategies in high-risk patients in Switzerland: a cost-effectiveness analysis

    by Nicolas Goossens, Osvaldo Ulises Garay, Cyrill Wolf, Louisa Elena Ambüehl, Vanessa Kugler, François R Girardin

    BACKGROUND: European and Swiss guidelines recommend hepatocellular carcinoma surveillance of high-risk patients every 6 months using ultrasound (US), with/without α-fetoprotein (AFP). Other surveillance strategies are available, but evidence of their comparative cost-effectiveness is lacking. This study evaluated the cost-effectiveness of current hepatocellular carcinoma surveillance strategies in Switzerland, including the novel GAAD (gender [biological sex], age, α-fetoprotein, protein induced by vitamin K absence or antagonist-II [PIVKA-II]) serum-based algorithm in high-risk patients. METHODS: A micro-simulated Markov model estimated the cost-effectiveness of hepatocellular carcinoma surveillance strategies (no surveillance, US, US+AFP, GAAD) performed at 6-monthly intervals in a simulated cohort of 100,000 patients with compensated liver cirrhosis over a lifetime horizon. Performance parameters were sourced from published meta-analyses and multicentre study data. Epidemiological parameters were estimated based on literature identified during a previous systematic literature review. Similarly, utility parameters were sourced from published literature. Costs were sourced from TARMED, the Analysis List, the Swiss Federal Statistical Office, publicly available data and published literature. Primary outcomes were life years lived, quality-adjusted life years, and costs per patient and per cohort. The cost-effectiveness of each strategy was analysed through incremental cost-effectiveness ratios at a cost-effectiveness threshold of Swiss Franc (CHF) 100,000/quality-adjusted life year. RESULTS: Overall, the total costs and quality-adjusted life years per patient, respectively, were CHF 43,493.61 and 5.893 for no surveillance; CHF 48,702.79 and 6.018 for US; CHF 49,980.60 and 6.042 for US+AFP; and CHF 49,983.10 and 6.048 for GAAD. Compared with US+AFP and US alone, GAAD was cost-effective, with higher quality-adjusted life years and the highest rate of early-stage hepatocellular carcinoma detection (56%). Compared with no surveillance, incremental cost-effectiveness ratios for US, US+AFP and GAAD were considered to be cost-effective, ranging from CHF 41,509.01 to CHF 43,321.81. CONCLUSIONS: The current model indicates that hepatocellular carcinoma surveillance with any of these strategies was cost-effective in Switzerland. GAAD was nearly cost-neutral versus US+AFP, although these findings were dependent on the performance of GAAD and operator-dependent US combined with AFP. Compared with US alone, GAAD was the most cost-effective strategy. Further investigations are required to confirm these findings and to optimise hepatocellular carcinoma surveillance.

  • Open Access

    Preformed donor-specific antibodies are associated with acute rejection and biliary complications after liver transplantation: A Swiss Transplant Cohort Study analysis

    by Julien Vionnet, Sylvie Ferrari-Lacraz, Linard David Hoessly, Antonio Mancarella, Yannick D. Müller, Stefan Schaub, Jakob Nilsson, Urs Wirthmüller, Susanne Stampf, Michael Koller, et al.

    The impact of preformed donor-specific antibodies (DSA) in liver transplantation (LT) remains controversial despite evidence linking their presence to an increased risk of early allograft damage, as well as antibody- and T-cell–mediated rejection. In this nationwide analysis, preformed DSA were assessed using single-antigen bead assays [positive if mean fluorescence intensity (MFI) ≥1000]. This study included all LT recipients enrolled in the Swiss Transplant Cohort Study (STCS) who underwent LT between 2014 and 2016. One-year post-LT outcomes, including cumulative allograft and patient survival, as well as the incidence of biliary, vascular, and infectious complications, were compared between DSA-positive (DSA+) and DSA-negative (DSA−) individuals. Among 321 LT performed in 306 patients, preformed DSA were detected in 92 (28.7%) and more frequently observed in patients with a history of prior transplantation ( p =0.008) or autoimmune liver disease ( p =0.036). Class I and II DSA were present in 48.9% and 71.1% of DSA+ cases, with concomitant class I and II DSA in 20.7%. The median (IQR) cumulative MFI (cMFI) of the preformed DSA was 3768 (1875–10,537), and 52.2% of DSA+ patients harbored multiple DSA. While overall patient survival did not differ between DSA+ and DSA− individuals, DSA+ patients with cMFI ≥5000 exhibited a higher incidence of allograft failure and biopsy-proven rejection. Multivariate analysis revealed that the presence of preformed DSA was independently associated with biliary complications (HR 2.26, 95% CI 1.17–4.37, p =0.02) but not with vascular or infectious complications. In summary, preformed DSA were associated with biliary complications, increased rejection, and reduced allograft survival. These findings suggest pre-transplant immunological risk assessment and the need for tailored immunosuppressive strategies in LT.


  • Open Access

    Liver transplantation indications and strategies in polycystic liver disease: A european survey

    by Renée Duijzer, Ian P.J. Alwayn, Flaminia Ferri, Frederik Nevens, George Papatheodoridis, Jef Verbeek, Jordi Colmenero, Nicolas Goossens, Piotr Milkiewicz, Richard Taubert, et al.

    Background & Aims: Liver transplantation (LT) remains the only cure for severe polycystic liver disease (PLD). However, LT indications and strategies vary across Europe, resulting in (unwanted) practice variation and unequal access to care for patients with PLD. This study aimed to (1) identify existing PLD-specific LT criteria across European countries, (2) assess which criteria are considered relevant by specialist, and (3) map the variation in liver-kidney transplant strategies among patients with autosomal dominant polycystic kidney disease (ADPKD). Methods: National PLD-specific LT criteria were collected, and if unavailable ERN RARE-Liver representatives from that country were asked to provide information. An online survey was conducted amongst hepatologists, LT surgeons, and nephrologists managing patients with PLD. The survey assessed relevant LT indications/listing requirements, clinical case evaluations, and explored preferences for liver-kidney transplantation in patients with ADPKD. Results: Defined LT criteria for patients with PLD were available in only 8 of the 17 assessed countries and showed substantial variation. Sixty-nine clinicians (43 hepatologists, 15 surgeons, 11 nephrologists), predominantly from LT centers (75.4%), completed the survey. Key LT indications were recurrent liver cyst infections (78.3%), significant impaired quality of life (75.4%), and severe malnutrition (75.4%). In ADPKD simultaneous liver-kidney transplantation (SLK) was preferred by 40.4% of respondents, primarily due the favorable immunological profile (47.6%) and prevention of renal failure (33.3%). In contrast, those favoring a liver-first approach (30.8%), followed by sequential kidney transplant, highlighted the potential harm to the kidney graft during SLK (62.5%). Conclusions: Uniform PLD-specific LT criteria in Europe are lacking. While recurrent liver cyst infections, decreased quality of life, and malnutrition are widely recognized as crucial LT indications, they are insufficiently reflected in existing criteria, contributing to unequal access to LT. Moreover, considerable variation exists in liver-kidney transplantation for ADPKD patients, with a current lack of evidence to support one approach over another.


  • Top Cited Papers
    Open Access

    Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study

    by Beat Moeckli, Charles-Henri Wassmer, Sofia El Hajji, Rohan Kumar, Joana Rodrigues Ribeiro, Parissa Tabrizian, Hao Feng, Gabriel Schnickel, Anand V. Kulkarni, Manon Allaire, et al.

    Background and Aims: Immune checkpoint inhibitors (ICIs) are increasingly used in patients with advanced HCC patients awaiting liver transplantation (LT). However, concerns about the risk of posttransplant rejection persist. Approach and Results: We conducted an international retrospective cohort study including 119 HCC patients who received ICIs prior to LT. We analyzed the incidence of allograft rejection, graft loss, and posttransplant recurrence with a particular focus on the washout period between the last ICI dose and LT. In this study, 24 of the 119 (20.2%) patients experienced allograft rejection with a median time to rejection of 9 days (IQR 6–10) post-LT. A linear relationship was observed between shorter washout periods and higher rejection risk. Washout periods p<0.001) and between 30 and 50 days (OR: 9.48, 95% CI 2.47–46.8, p=0.002) were significantly associated with higher rejection rates in the univariate analysis compared to the washout period above 50 days. Graft loss as a result of rejection occurred in 6 patients (25%) with rejection. No factors related to grafts were associated with rejection. A longer washout period was not associated with a lower recurrence-free survival posttransplantation at 36 months (71% vs. 67%, p=0.71). Conclusions: Our findings suggest that a washout period longer than 50 days for ICIs before LT appears to be safe with respect to rejection risk. While these results may help guide clinical decision-making, future prospective studies are essential to establish definitive guidelines.


  • Open Access

    The Role of Extrahepatic Features on the Development and Management of Hepatocellular Carcinoma in Steatotic Liver Disease

    by Lucia Zampaglione, Jacopo Ferrari, Naik Vietti Violi, Nicolas Goossens

    As the most common type of primary liver cancer, hepatocellular carcinoma (HCC) is reportedly the third leading cause of cancer-related death globally. Advanced steatotic liver disease (SLD) emerges as the most prominent contributor to HCC worldwide. In this paper, we review the extrahepatic features of metabolic dysfunction-associated SLD that exacerbate the risk for HCC, including insulin resistance, obesity-related factors such as physical inactivity and dietary patterns, as well as influences of genetics, ethnicity, gender-specific hormonal differences, alcohol-associated liver disease (ALD), smoking habits, and alterations in gut microbiota. Additionally, the mechanisms underlying how these extrahepatic features contribute to the development, as well as the detection and surveillance of HCC, are elaborated. With a better understanding of these factors, targeted interventions can be designed to prevent HCC development or ameliorate its clinical outcomes.


  • Open Access

    Variable Intrafamilial Expression of ABCB4 Disease

    by Lucia Zampaglione, Anne-Laure Rougemont, Laura Rubbia-Brandt, Marc Abramowicz, Michel Guipponi, Enrica Marchionni, Valerie McLin, Nicolas Goossens

    Progressive familial intrahepatic cholestasis type 3 (PFIC3) is a rare cholestatic liver disease with autosomal recessive inheritance caused by mutations in the ABCB4 gene. The clinical presentation of PFIC3 varies significantly, displaying incomplete penetrance without clear genotype-phenotype correlations. As such, the suitability of living-related liver donation for children with advanced disease has been questioned. We report here the long-term follow-up of a patient with PFIC3 resulting in decompensated cirrhosis at 11 years who successfully underwent living donor liver transplantation from his father, who carried the same ABCB4 homozygous mutation.


  • Open Access

    Stéatose hépatique non alcoolique : diagnostic et traitement en 2022

    by Nikoletta Maria Tagkou, Nicolas Goossens

    Résumé: La NAFLD (Non Alcoholic Fatty Liver Disease) est la manifestation hépatique d’un trouble métabolique multisystémique. Elle est la principale cause de maladie hépatique au niveau mondial, avec une prévalence croissante. Bien qu’il s’agisse principalement d’une maladie silencieuse à évolution lente, certains patients présentent un risque élevé de progression de la maladie et d’issues plus graves telles que la cirrhose, le carcinome hépatocellulaire et la transplantation hépatique. Malgré les multiples études menées et les nombreux essais cliniques en cours, il n’existe pas de médicaments approuvés pour la NAFLD/NASH (Non Alcoholic Steato-Hepatitis), et le traitement doit donc se fonder sur des stratégies de modification du mode de vie. Cette revue explorera la définition et l’épidémiologie courantes de la NAFLD et de la NASH ainsi que les facteurs de risque et les conséquences de la maladie, tout en résumant les recommandations existantes pour le diagnostic, la stratification du risque et la prise en charge de la maladie.


  • Open Access

    Impact of Maternal Obesity on Liver Disease in the Offspring: A Comprehensive Transcriptomic Analysis and Confirmation of Results in a Murine Model

    by Beat Moeckli, Vaihere Delaune, Julien Prados, Matthieu Tihy, Andrea Peloso, Graziano Oldani, Thomas Delmi, Florence Slits, Quentin Gex, Laura Rubbia-Brandt, et al.

    The global obesity epidemic particularly affects women of reproductive age. Offspring of obese mothers suffer from an increased risk of liver disease but the molecular mechanisms involved remain unknown. We performed an integrative genomic analysis of datasets that investigated the impact of maternal obesity on the hepatic gene expression profile of the offspring in mice. Furthermore, we developed a murine model of maternal obesity and studied the development of liver disease and the gene expression profile of the top dysregulated genes by quantitative real-time polymerase chain reaction (qPCR). Our data are available for interactive exploration on our companion webpage. We identified five publicly available datasets relevant to our research question. Pathways involved in metabolism, the innate immune system, the clotting cascade, and the cell cycle were consistently dysregulated in the offspring of obese mothers. Concerning genes involved in the development of liver disease, Egfr, Vegfb, Wnt2,Pparg and six other genes were dysregulated in multiple independent datasets. In our own model, we observed a higher tendency towards the development of non-alcoholic liver disease (60 vs. 20%) and higher levels of alanine aminotransferase (41.0 vs. 12.5 IU/l, p = 0.008) in female offspring of obese mothers. Male offspring presented higher levels of liver fibrosis (2.4 vs. 0.6% relative surface area, p = 0.045). In a qPCR gene expression analysis of our own samples, we found Fgf21, Pparg, Ppard, and Casp6 to be dysregulated by maternal obesity. Maternal obesity represents a looming threat to the liver health of future generations. Our comprehensive transcriptomic analysis will help to better understand the mechanisms of the development of liver disease in the offspring of obese mothers and can give rise to further explorations.